Paclitaxel

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

Codes ATC: L01CD01

Indication	Malignant neoplasms of nasopharynx Code ICD11: 2B6B.Z
INN	Paclitaxel
Type de médicament	Chemical agent
Type de liste	Liste complémentaire
Formulations	**Parenteral > General injections > IV:** 6 mg per mL
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Balises	Cancer
Wikipédia	Paclitaxel
DrugBank	Paclitaxel

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for nasopharyngeal cancer is attached.